CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.

Saved in:
Bibliographic Details
Title: CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.
Authors: Chen L; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, USA.; Broad Institute, Cambridge, Massachusetts, USA., Alexe G; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, USA.; Broad Institute, Cambridge, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Bioinformatics Graduate Program, Boston University, Boston, Massachusetts, USA., Dharia NV; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, USA.; Broad Institute, Cambridge, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Ross L; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, USA., Iniguez AB; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, USA.; Broad Institute, Cambridge, Massachusetts, USA., Conway AS; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, USA., Wang EJ; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, USA., Veschi V; Cell and Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA., Lam N; Cell and Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA., Qi J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Gustafson WC; Department of Pediatrics, Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Nasholm N; Department of Pediatrics, Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Vazquez F; Broad Institute, Cambridge, Massachusetts, USA., Weir BA; Broad Institute, Cambridge, Massachusetts, USA., Cowley GS; Broad Institute, Cambridge, Massachusetts, USA., Ali LD; Broad Institute, Cambridge, Massachusetts, USA., Pantel S; Broad Institute, Cambridge, Massachusetts, USA., Jiang G; Broad Institute, Cambridge, Massachusetts, USA., Harrington WF; Broad Institute, Cambridge, Massachusetts, USA., Lee Y; Broad Institute, Cambridge, Massachusetts, USA., Goodale A; Broad Institute, Cambridge, Massachusetts, USA., Lubonja R; Broad Institute, Cambridge, Massachusetts, USA., Krill-Burger JM; Broad Institute, Cambridge, Massachusetts, USA., Meyers RM; Broad Institute, Cambridge, Massachusetts, USA., Tsherniak A; Broad Institute, Cambridge, Massachusetts, USA., Root DE; Broad Institute, Cambridge, Massachusetts, USA., Bradner JE; Harvard Medical School, Boston, Massachusetts, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA., Golub TR; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, USA.; Broad Institute, Cambridge, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Roberts CW; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, USA.; Comprehensive Cancer Center and Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA., Hahn WC; Broad Institute, Cambridge, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Weiss WA; Department of Pediatrics, Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA.; Department of Neurology, Neurological Surgery, Brain Tumor Research Center, UCSF, San Francisco, California, USA., Thiele CJ; Cell and Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, USA.; Broad Institute, Cambridge, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.
Source: The Journal of clinical investigation [J Clin Invest] 2018 Jan 02; Vol. 128 (1), pp. 446-462. Date of Electronic Publication: 2017 Dec 04.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1558-8238
DOI:10.1172/JCI90793